CArvedilol SR in Patients With REduced Strain and Preserved Ejection Fraction Heart Failure (CARE-preserved HF): A Prospective Randomized, Double-Blinded, Multicenter Study

  • End date
    Aug 30, 2024
  • participants needed
  • sponsor
    Seoul National University Bundang Hospital
Updated on 18 October 2022


Beta-blockers improve clinical outcomes in heart failure and reduced ejection fraction (HFrEF); but not in those with preserved EF. Global longitudinal strain (GLS) is a prognostic factor independent of left ventricular ejection fraction (LVEF). In a retrospective with 1969 patients with HF and LVEF of ≥40%, beta-blocker was associated with improved survival in those with low GLS (GLS <14%), but not in those with GLS ≥14%. In this prospective, randomized clinical study, the investigators will assess the effect of carvedilol in patients with HF and EF > 40% and GLS < 14% and N-terminal pro-B-type natriuretic peptide (NT-proBNP) > 400 pg/mL. The primary endpoint is the time-averaged proportional changes in NT-proBNP level from baseline through month 3. The secondary endpoints include the change in NT -proBNP at month 3 and month 6.

Condition Heart Failure With Preserved Ejection Fraction, Beta Blocker, Myocardial Strain
Treatment Placebo, Carvedilol
Clinical Study IdentifierNCT05553314
SponsorSeoul National University Bundang Hospital
Last Modified on18 October 2022


Yes No Not Sure

Inclusion Criteria

HFpEF > 40%
GLS < 14%
NT0proBNP > 400 pg/ml
no atrial fibrillation
beta-blocker naive

Exclusion Criteria

systolic blood pressure < 110 mmHg, heart rate < 60 beats/min
contra-indication to beta-blockers
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note